CTLA4 and type 1 diabetes mellitus: HbA1c measurements within 30 days of ICI-induced IDDM diagnosis were performed for 19 patients: 10 were receiving anti-PD1/PD-L1 antibodies in monotherapy, 4 were on anti-PD1/PD-L1 and anti-CTLA4 antibodies in combination, 3 were being treated with other anti-PD1/PD-L1-based combinations and 2 were in anti-PD1/PD-L1-based randomized clinical trials.